{"id":51658,"date":"2022-12-07T12:02:24","date_gmt":"2022-12-07T11:02:24","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-alpha-emitters-strategic-business-report-2022-featuring-actinium-pharmaceuticals-alpha-tau-medical-bayer-and-fusion-pharma-among-others-researchandmarkets-com\/"},"modified":"2022-12-07T12:02:24","modified_gmt":"2022-12-07T11:02:24","slug":"global-alpha-emitters-strategic-business-report-2022-featuring-actinium-pharmaceuticals-alpha-tau-medical-bayer-and-fusion-pharma-among-others-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-alpha-emitters-strategic-business-report-2022-featuring-actinium-pharmaceuticals-alpha-tau-medical-bayer-and-fusion-pharma-among-others-researchandmarkets-com\/","title":{"rendered":"Global Alpha Emitters Strategic Business Report 2022: Featuring Actinium Pharmaceuticals, Alpha Tau Medical, Bayer and Fusion Pharma Among Others – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Alpha Emitters: Global Strategic Business Report”<\/a> has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global market for Alpha Emitters estimated at US$684.5 Million in the year 2020, is projected to reach a revised size of US$2.5 Billion by 2027, growing at a CAGR of 20.6% over the analysis period 2020-2027.\n<\/p>\n

\nBone Metastasis, one of the segments analyzed in the report, is projected to record a 20.1% CAGR and reach US$888.5 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Ovarian Cancer segment is readjusted to a revised 21.8% CAGR for the next 7-year period.\n<\/p>\n

\nThe U.S. Market is Estimated at $203.1 Million, While China is Forecast to Grow at 19.9% CAGR<\/strong>\n<\/p>\n

\nThe Alpha Emitters market in the U.S. is estimated at US$203.1 Million in the year 2020. China, the world’s second largest economy, is forecast to reach a projected market size of US$437.5 Million by the year 2027 trailing a CAGR of 19.9% over the analysis period 2020 to 2027.\n<\/p>\n

\nAmong the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 18.4% and 17.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 15.3% CAGR.\n<\/p>\n

\nPancreatic Cancer Segment to Record 21.2% CAGR<\/strong>\n<\/p>\n

\nIn the global Pancreatic Cancer segment, USA, Canada, Japan, China and Europe will drive the 21.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$94.5 Million in the year 2020 will reach a projected size of US$357.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.\n<\/p>\n

\nSelect Competitors (Total 12 Featured) –<\/strong>\n<\/p>\n